Price Chart

Profile

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
URL https://www.acumenpharm.com
Investor Relations URL https://investors.acumenpharm.com/
HQ State/Province Virginia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 27, 2024 (est.)
Last Earnings Release Nov. 13, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
URL https://www.acumenpharm.com
Investor Relations URL https://investors.acumenpharm.com/
HQ State/Province Virginia
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 27, 2024 (est.)
Last Earnings Release Nov. 13, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A